Avalo Therapeutics Inc

AVTX | $13.0 6.47% 4.76% 71K

(0.0% 1d) (168.6% 1m) (337.7% 1y) (0.0% 2d) (6.5% 3d) (8.2% 7d) (-11.97% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 13,443,690
https://www.cerecor.com
Sec Filling | Patents | 31 employees

(United States) Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

monoclonal antibodies antibody covid respiratory treatment

add to watch list Paper trade email alert is off

Press-releases

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
AVTX | $13.0 6.47% 4.76% 71K

Manufacturing

| -33.09% | O: -22.8% H: 15.52% C: 1.07%
ICLR | News | $306.45 2.86% 2.68% 5

Health Technology

| -9.15% | O: -2.95% H: 0.0% C: -1.43%
BIIB | $193.18 -0.48% 5.8% 1.2M

Health Technology

| -10.35% | O: -1.11% H: 0.16% C: -2.56%
biotech leaders therapeutics

Avalo Reports 2023 Financial Results and Provides Business Updates
Published: 2024-03-29 (Crawled : 20:00) - globenewswire.com
AVTX | $13.0 6.47% 4.76% 71K

Manufacturing

| Email alert Add to watchlist
business financial results

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
SLRN | $4.6 -4.56% -4.78% 2M

| -31.85% | O: 0.15% H: 3.7% C: -0.15%
AVTX | $13.0 6.47% 4.76% 71K

Manufacturing

| 173.68% | O: 295.16% H: 0.0% C: 0.0%
million

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
Published: 2023-12-27 (Crawled : 12:00) - globenewswire.com
AVTX | $13.0 6.47% 4.76% 71K

Manufacturing

| 4.17% | O: -5.77% H: 6.94% C: 6.12%
JNJ | News | $149.56 0.3% 0.03% 140K

Health Technology

| -3.41% | O: 0.39% H: 0.0% C: 0.0%
therapeutics

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
Published: 2023-12-07 (Crawled : 12:00) - globenewswire.com
AVTX | $13.0 6.47% 4.76% 71K

Manufacturing